Abstract
BackgroundA large amount of information has been collected on the molecular tumorigenesis of thyroid cancer. A low expression of c-KIT gene has been reported during the transformation of normal thyroid epithelium to papillary carcinoma suggesting a possible role of the gene in the differentiation of thyroid tissue rather than in the proliferation. The initial presentation of thyroid carcinoma is through a nodule and the best way nowadays to evaluate it is by fine-needle aspiration (FNA). However many thyroid FNAs are not definitively benign or malignant, yielding an indeterminate or suspicious diagnosis which ranges from 10 to 25% of FNAs. BRAF mutational analysis is commonly used to assess the malignancy of thyroid nodules but unfortunately it still leaves indeterminate diagnoses. The development of molecular initial diagnostic tests for evaluating a thyroid nodule is needed in order to define optimal surgical approach for patients with uncertain diagnosis pre- and intra-operatively.MethodsIn this study we extracted RNA from 82 FNA smears, 46 malignant and 36 benign at the histology, in order to evaluate by quantitative Real Time PCR the expression levels of c-KIT gene.ResultsWe have found a highly preferential decrease rather than increase in transcript of c-KIT in malignant thyroid lesions compared to the benign ones. To explore the diagnostic utility of c-KIT expression in thyroid nodules, its expression values were divided in four arbitrarily defined classes, with class I characterized by the complete silencing of the gene. Class I and IV represented the two most informative groups, with 100% of the samples found malignant or benign respectively. The molecular analysis was proven by ROC (receiver operating characteristic) analysis to be highly specific and sensitive improving the cytological diagnostic accuracy of 15%.ConclusionWe propose the use of BRAF test (after uncertain cytological diagnosis) to assess the malignancy of thyroid nodules at first, then the use of the c-KIT expression to ultimately assess the diagnosis of the nodules that otherwise would remain suspicious. The c-KIT expression-based classification is highly accurate and may provide a tool to overcome the difficulties in today's preoperative diagnosis of thyroid suspicious malignancies.
Highlights
Thyroid carcinoma represents 90% of all endocrine malignancies and about 1% of all human malignancies, with an increasing incidence [1]
A number of tumour types are associated with activation of c-KIT through its overexpression or through activating mutations [7,9,10,11], while in highly metastatic melanomas, breast cancer and thyroid carcinoma the progression into a malignant phenotype correlates mostly with loss of c-KIT expression [12,13,14,15,16]
Expression and genotyping of c-KIT receptor in benign and malignant thyroid lesions c-KIT expression was analyzed by quantitative Real-Time PCR (qPCR) in a set of 82 fine-needle aspiration cytology (FNAC), histologically diagnosed as 36 benign and 46 malignant thyroid nodules (Table 2)
Summary
Thyroid carcinoma represents 90% of all endocrine malignancies and about 1% of all human malignancies, with an increasing incidence [1]. The proto-oncogene c-KIT is a type III receptor tyrosine-kinase, cellular homolog of the viral oncogene of the feline sarcoma retrovirus HZ4-FeSV It plays various roles in haematopoiesis, melanogenesis and spermatogenesis, and in the development of the interstitial cells of Cajal. In 2004 Mazzanti et al [18], by using a microarray assay, were able to identify, out of thousands of genes, c-KIT as one of the most significant down-expressed gene in PTC compared to benign lesions. Other laboratories confirmed this result by using quantitative Real-Time PCR (qPCR) [19,20]. The development of molecular initial diagnostic tests for evaluating a thyroid nodule is needed in order to define optimal surgical approach for patients with uncertain diagnosis pre- and intra-operatively
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have